PNX Metals Ltd

PNX Metals drilling prospects near Hayes Creek Project as DFS continues

PNX Metals Ltd (ASX:PNX) managing director and CEO James Fox speaks to Proactive Investors about the multi-commodity exploration and development company's Northern Territory operations. The company is focused on the development of its flagship Hayes Creek zinc-gold-silver project, and exploration at a number of neighbouring sites. 

Fox says, "everything that we do in the Northern Territory - with our exploration strategy, with the project development strategy - is all tied into the same thing. We're looking to enhance and expand our resource base, improve the very good economics of the project, and make it bigger, better, stronger, fitter, faster."

A drilling program is underway at the Fountain Head prospect, with first assay results due in a matter of weeks. A maiden drilling program is also set for the Kilfoyle prospect later this year, which will be 50% funded by the state government. In the meantime, funding and development works at Hayes Creek are ongoing, as PNX Metals continues its Definitive Feasibility Study (DFS) there.

Quick facts: PNX Metals Ltd

Price: $0.01

Market: ASX
Market Cap: $21.92 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of PNX Metals Ltd named herein, including the promotion by the Company of PNX Metals Ltd in any Content on the Site, the Company receives from...



Full interview: Scancell back in the clinic with a phase II trial of its...

Scancell Holdings PLC's (LON:SCLP) Cliff Holloway tells Proactive London's Andrew Scott they've begun the UK arm of the phase II trial of its flagship skin cancer treatment. The trial is testing the safety and efficacy of SCIB1 in metastatic melanoma patients who are also receiving Merck’s...

8 hours, 15 minutes ago

2 min read